---
title: "NVA237 Versus Placebo 12-week Efficacy Study"
description: "The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigatio"
url: "https://www.clareohealth.com/clinical-trials/NCT01709864"
---

The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug will be tested against a placebo treatment. The primary criterion to assess efficacy will be the difference between the serial lung function measurements of patients who have been treated for 12 weeks with NVA237 versus those that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1 testing) will be conducted and the "area under the curve" will be the measure for the ability to breathe.

## Key Facts

**ID:** NCT01709864
**Status:** COMPLETED
**Phase:** PHASE3
**Type:** INTERVENTIONAL
**Enrollment:** 440
**Sponsor:** Novartis Pharmaceuticals

## About This Study

This clinical trial is testing NVA237, a new inhaled medication, to see if it is effective and safe for people with stable Chronic Obstructive Pulmonary Disease (COPD). Participants will be compared to those receiving a placebo, which is an inactive treatment, over a 12-week period.

## Conditions

- Chronic Obstructive Pulmonary Disease

## Interventions

**DRUG: NVA237**
NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.

**DRUG: Placebo**
Placebo powder for inhalation in single-dose capsules (matching those for NVA237).

## Eligibility

Inclusion criteria: 1.

## Who Can Participate

**Minimum age:** 40

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Novartis Investigative Site, Homewood, Alabama, United States
- Novartis Investigative Site, Jasper, Alabama, United States
- Novartis Investigative Site, *See Various Dept.'s*, Arizona, United States
- Novartis Investigative Site, Tucson, Arizona, United States
- Novartis Investigative Site, Fountain Valley, California, United States
- Novartis Investigative Site, Fullerton, California, United States
- Novartis Investigative Site, Los Angeles, California, United States
- Novartis Investigative Site, Los Angeles, California, United States
- Novartis Investigative Site, Riverside, California, United States
- Novartis Investigative Site, San Diego, California, United States
- Novartis Investigative Site, San Diego, California, United States
- Novartis Investigative Site, Brandon, Florida, United States
- Novartis Investigative Site, Clearwater, Florida, United States
- Novartis Investigative Site, DeFuniak Springs, Florida, United States
- Novartis Investigative Site, Edgewater, Florida, United States
- Novartis Investigative Site, Fort Lauderdale, Florida, United States
- Novartis Investigative Site, Hialeah, Florida, United States
- Novartis Investigative Site, Miami, Florida, United States
- Novartis Investigative Site, Miami, Florida, United States
- Novartis Investigative Site, Miami, Florida, United States
- Novartis Investigative Site, Miami, Florida, United States
- Novartis Investigative Site, Pensacola, Florida, United States
- Novartis Investigative Site, Pompano Beach, Florida, United States
- Novartis Investigative Site, Port Orange, Florida, United States
- Novartis Investigative Site, Sarasota, Florida, United States
- Novartis Investigative Site, South Miami, Florida, United States
- Novartis Investigative Site, Summerfield, Florida, United States
- Novartis Investigative Site, Tamarac, Florida, United States
- Novartis Investigative Site, Tampa, Florida, United States
- Novartis Investigative Site, Winter Park, Florida, United States
- Novartis Investigative Site, Las Vegas, Nevada, United States
- Novartis Investigative Site, Las Vegas, Nevada, United States
- Novartis Investigative Site, Charlotte, North Carolina, United States
- Novartis Investigative Site, Raleigh, North Carolina, United States
- Novartis Investigative Site, Shelby, North Carolina, United States
- Novartis Investigative Site, Charleston, South Carolina, United States
- Novartis Investigative Site, Charleston, South Carolina, United States
- Novartis Investigative Site, Columbia, South Carolina, United States
- Novartis Investigative Site, Easley, South Carolina, United States
- Novartis Investigative Site, Gaffney, South Carolina, United States
- Novartis Investigative Site, Greenville, South Carolina, United States
- Novartis Investigative Site, Ninety Six, South Carolina, United States
- Novartis Investigative Site, Rock Hll, South Carolina, United States
- Novartis Investigative Site, Seneca, South Carolina, United States
- Novartis Investigative Site, Simpsonville, South Carolina, United States
- Novartis Investigative Site, Spartanburg, South Carolina, United States
- Novartis Investigative Site, Union, South Carolina, United States
- Novartis Investigative Site, Amarillo, Texas, United States
- Novartis Investigative Site, Arlington, Texas, United States
- Novartis Investigative Site, Arlington, Texas, United States
- Novartis Investigative Site, Beaumont, Texas, United States
- Novartis Investigative Site, Dallas, Texas, United States
- Novartis Investigative Site, Huntsville, Texas, United States
- Novartis Investigative Site, Waco, Texas, United States

## Contact Information

## Important Dates

**Study start:** November 1, 2012

**Completion date:** October 1, 2013

**Last updated:** March 4, 2015

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have stable, symptomatic COPD and are looking for new treatment options.
- Your current medications are not adequately controlling your symptoms.
- You are between 40 and 80 years old and have a history of smoking.

### Questions to Ask

- Am I eligible for this trial based on my COPD symptoms and history?
- How does NVA237 compare to my current treatment options?
- What are the potential side effects of NVA237?
- How will my lung function be monitored during the trial?
- What happens if I experience side effects while participating?
- Where will the trial take place, and how often will I need to visit?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01709864)
